Earnings Mastery
  • Politics
  • Business
  • Investing
  • World
No Result
View All Result
  • Politics
  • Business
  • Investing
  • World
No Result
View All Result
Earnings Mastery
No Result
View All Result
Home Investing

Regeneron stock crashes on COPD data: here’s why I’m buying REGN today

May 31, 2025
in Investing
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) crashed more than 15% this morning on disappointing data from Phase 3 trials of its experimental drug itepekimab.

Itepekimab is a drug candidate for chronic obstructive pulmonary disease (COPD) that the biotech firm developed with Paris headquartered Sanofi.

Including today’s plummet, REGN shares are down nearly 35% versus their year-to-date high.

Regeneron stock is going for a huge discount

Despite an unusually difficult first half of 2025, there’s ample reason, including solid fundamentals, to buy Regeneron stock at current levels.  

In 2024, the pharmaceutical behemoth reported $14.2 billion in revenue on $4.4 billion worth of net income, both ahead of consensus.

REGN’s net profit margin stood at just under 27% last year, underscoring its ability to generate substantial earnings from its operations.

From a valuation standpoint, Regeneron shares appear attractive as well.

They’re now going for a price-to-earnings multiple of less than 13 (trailing), well below their historical average and biotech sector median of about 27.

This discount suggests that markets may be undervaluing the company’s earnings potential and growth prospects at the time of writing.

REGN still has exposure to the COPD market

While itepekimab late-stage trials miss the mark, Regeneron flagship product, Dupixent, already has FDA approval for the treatment of COPD, marking its sixth US indication since initial approval for atopic dermatitis.

This suggests that REGN remains well-positioned in the respiratory conditions market even though its itepekimab disappointed on Friday.

Additionally, the biotechnology company spent $256 million earlier this month to buy 23andMe assets, which expand its footprint in genetic research and personalized medicine.

This said acquisition could bolster the company’s drug development pipeline and support long-term growth.

Note that Regeneron stock currently pays a dividend yield of 0.72% as well, which makes it somewhat more attractive to own in 2025.

How analysts recommend playing REGN shares

Investors should also note that analysts remain bullish on Regeneron shares despite the itepekimab setback today.

Citi analysts recently upgraded REGN stock to “buy”, citing stabilising fundamentals and near-term catalysts, including product developments, for instance, fianlimab.

On Friday, analysts at Cantor Fitzgerald also reiterated the biotech stock at “overweight”.

In a note to clients, the investment bank agreed that the disappointing late-stage data could hurt Regeneron for a while but expressed confidence in the firm’s long-term trajectory.

Cantor currently has a $695 price target on Regeneron Pharmaceuticals that indicates potential for a more than 40% upside from current levels.

All in all, while the trial results for itepekimab have introduced short-term volatility, the Nasdaq listed firm’s strong financials, diversified product portfolio, and strategic initiatives position it well for sustained growth moving forward.

Therefore, the company’s current stock price, reflecting a significant discount, offers a potential entry point for investors seeking exposure to a resilient and innovative biotech name.

The post Regeneron stock crashes on COPD data: here’s why I’m buying REGN today appeared first on Invezz

Previous Post

US picks Palantir as data analysis partner, but why you shouldn’t jump into PLTR

Next Post

Adobe stock price is cheap: is it a good buy?

Next Post
Adobe stock price is cheap: is it a good buy?

Adobe stock price is cheap: is it a good buy?

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    Will the ECB rate cut drive the DAX Index to an all-time high?

    June 2, 2025
    Why experts say SpaceX is one of the world’s most important companies

    Why experts say SpaceX is one of the world’s most important companies

    June 2, 2025
    Wedbush reveals best AI stock picks for the second half of 2025

    Wedbush reveals best AI stock picks for the second half of 2025

    June 2, 2025
    China’s manufacturing PMI edges up despite ongoing trade tensions

    China’s manufacturing PMI edges up despite ongoing trade tensions

    June 2, 2025
    Europe markets open: STOXX 600 dips 0.2% on renewed US tariff threats; auto sectors under pressure

    Europe markets open: STOXX 600 dips 0.2% on renewed US tariff threats; auto sectors under pressure

    June 2, 2025
    ‘Bitcoin-style encryption’ for XChat? Musk’s claim sparks debate

    ‘Bitcoin-style encryption’ for XChat? Musk’s claim sparks debate

    June 2, 2025

    Disclaimer: EarningsMastery.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Popular

    PepeX gains steam Ethereum and Solana prices crash

    PepeX gains steam Ethereum and Solana prices crash

    March 30, 2025

    Latest

    Will the ECB rate cut drive the DAX Index to an all-time high?

    June 2, 2025
    Why experts say SpaceX is one of the world’s most important companies

    Why experts say SpaceX is one of the world’s most important companies

    June 2, 2025
    Wedbush reveals best AI stock picks for the second half of 2025

    Wedbush reveals best AI stock picks for the second half of 2025

    June 2, 2025
    • About us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 earningsmastery.com | All Rights Reserved

    No Result
    View All Result
    • Politics
    • Business
    • Investing
    • World

    Copyright © 2025 earningsmastery.com | All Rights Reserved